Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized liposomal ciclosporin A for prevention of bronchiolitis obliterans syndrome after lung transplantation
2008-003800-73Phase 2Terminated
- Sponsor
- PARI Pharma
- Start
- Dec 2008
- Modality
- Small Molecules, Peptides, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of liposomal ciclosporin A in Bronchiolitis Obliterans Syndrome (BOS) (3 arms), sponsored by PARI Pharma. Primary endpoint: Cumulative BOS-free survival. Started Dec 2008; status: terminated.
02
Drugs
liposomal ciclosporin A
03
Conditions
Bronchiolitis Obliterans Syndrome (BOS)
Beyond the preview
Go deeper on 2008-003800-73.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003800-73.